Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Our platform, designed with regulatory compliance in mind, enhances clinical research by using algorithms to sift through unstructured EMR data to identify life-threatening conditions. We create cutting-edge technologies that broaden access to groundbreaking healthcare solutions through Clinical Trials. Our dedicated team is committed to saving lives by facilitating access to therapeutic innovations that are still being researched. We strongly advocate that every patient should be informed and empowered regarding their potential to engage in clinical trials that could offer significant therapeutic benefits. As a forward-thinking healthcare AI research firm, we have created a computational platform that identifies patients who meet a detailed set of criteria for participation in clinical trials, ensuring that the most suitable candidates are considered for these critical studies. Through our work, we aim to revolutionize the way patients connect with life-changing treatment opportunities.
Description
Introducing a versatile API designed to seamlessly integrate with your diabetes management system, offering tailored therapeutic education and enhanced insights into blood glucose level fluctuations. This solution enables real-time risk predictions, fostering greater personalization and improved system regulation, while adeptly managing complex living scenarios characterized by rapid glucose variations. With advancements in telemedicine and retrospective analysis, patients receive robust decision-support tools. Currently, Hillo is developing the next iterations of its AI technology, which includes a therapeutic recommendation system aimed at preventing hypoglycemia and hyperglycemia, anticipated to achieve CE mark class IIB by 2020. Additionally, a new generation of the artificial pancreas is projected for release in 2021, addressing key limitations of existing systems through ultra-personalization driven by machine learning. This innovative approach marks the introduction of the first self-learning artificial intelligence capable of predicting blood glucose levels, aiming to secure a CE mark as a medical device, thereby transforming diabetes management for users. In essence, Hillo's advancements could significantly enhance the quality of life for individuals managing diabetes.
API Access
Has API
No
API Access
Has API
Yes
Integrations
MySQL
No
SQL
No
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Pricing Details
No price information available.
Free Trial
Yes
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Types of Training
Training Docs
No
Webinars
No
Live Training (Online)
Yes
In Person
No
Types of Training
Training Docs
Yes
Webinars
No
Live Training (Online)
No
In Person
Yes
Vendor Details
Company Name
Dyania Health
Founded
2019
Country
United States
Website
dyaniahealth.com
Vendor Details
Company Name
Hillo
Country
France
Website
www.hillo.ai/
Product Features
Natural Language Processing
Co-Reference Resolution
No
In-Database Text Analytics
No
Named Entity Recognition
No
Natural Language Generation (NLG)
No
Open Source Integrations
No
Parsing
No
Part-of-Speech Tagging
No
Sentence Segmentation
No
Stemming/Lemmatization
No
Tokenization
No